Phenotyping of cutaneous toxicities in patients with metastatic malignant melanoma treated with immune checkpoint blockade therapy at a UK tertiary care centre.

Abstract

Immune checkpoint blockade (ICB) therapy has transformed outcomes in patients with metastatic melanoma, however its use can be associated with the development of immune-related adverse events (irAEs)1 . Cutaneous irAEs are one of the commonest and earliest to present, occurring in up to 50% of patients2 and there is a growing effort to improve characterisation of their phenotype and clinical course. In the UK, only one large retrospective cohort has been reported, detailing 168 melanoma patients who developed cutaneous irAEs following ICB therapy over a 12-year period3 .